Pyridine-3-carboxamides as novel CB(2) agonists for analgesia

William L Mitchell; Gerard M P Giblin; Alan Naylor; Andrew J Eatherton; Brian P Slingsby; Anthony D Rawlings; Karamjit S Jandu; Carl P Haslam; Andrew J Brown; Paul Goldsmith; Nick M Clayton; Alex W Wilson; Iain P Chessell; Richard H Green; Andrew R Whittington; Ian D Wall

doi:10.1016/j.bmcl.2008.10.118

Pyridine-3-carboxamides as novel CB(2) agonists for analgesia

Bioorg Med Chem Lett. 2009 Jan 1;19(1):259-63. doi: 10.1016/j.bmcl.2008.10.118. Epub 2008 Nov 5.

Authors

William L Mitchell¹, Gerard M P Giblin, Alan Naylor, Andrew J Eatherton, Brian P Slingsby, Anthony D Rawlings, Karamjit S Jandu, Carl P Haslam, Andrew J Brown, Paul Goldsmith, Nick M Clayton, Alex W Wilson, Iain P Chessell, Richard H Green, Andrew R Whittington, Ian D Wall

Affiliation

¹ GlaxoSmithKline PLC, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK. [email protected]

PMID: 19010671
DOI: 10.1016/j.bmcl.2008.10.118

Abstract

We describe herein the medicinal chemistry approach which led to the discovery of a novel pyridine-3-carboxamide series of CB(2) receptor agonists. The SAR of this new template was evaluated and culminated in the identification of analogue 14a which demonstrated efficacy in an in vivo model of inflammatory pain.

MeSH terms

Amides / chemical synthesis
Amides / pharmacology
Amides / therapeutic use
Analgesia / methods
Analgesics / chemical synthesis*
Animals
Disease Models, Animal
Drug Discovery / methods
Inflammation
Pain / drug therapy
Pyridines / chemical synthesis*
Pyridines / pharmacology
Pyridines / therapeutic use*
Receptor, Cannabinoid, CB2 / agonists*
Structure-Activity Relationship

Substances

Amides
Analgesics
Pyridines
Receptor, Cannabinoid, CB2